FOLFIRI regimen as second-line treatment of metastatic gastric cancer: a retrospective analysis of efficacy, safety and prognostic factors

摘要: Background: There is no standard second-line treatment for mGC. FOLFIRI has shown efficacy and safety in this setting. Methods: Retrospective study of patients with mGC treated as a second line. We evaluated the response rate (RR), clinical benefit (CBR), progression-free survival (PFS), OS toxicity. Results: Sixty-six were included. Among evaluable there was an overall 20% stable disease 34%. Median PFS 3 months median 6 months. The number metastatic sites found to be prognostic factor (HR 2.23; p=0.005) 2.71; p<0.001). first line 1.71; p=0.045), but not 1.37; p=0.226). <7 ≥2 identified poor factors. defined two groups, group having worse 2.08; p=0.030) 2.97; p=0.003). most common grade 3-4 toxicity neutropenia 27%. Conclusions: effective well-tolerated are factors patients.